Core Viewpoint - Pagoda Biopharma-B (02565.HK) opened over 7% higher, indicating strong market interest and positive investor sentiment [2] Group 1 - The stock price increased by 7.03%, reaching 70 HKD [2] - The trading volume was 770,000 HKD, reflecting active market participation [2]

Core Viewpoint - The stock of Pagoda Biopharma-B (02565) opened over 7% higher, reflecting positive market sentiment following the announcement of a lock-up extension by cornerstone investor Yizhe Kangrui Pharmaceutical (Hong Kong) Co., Ltd. [1] Group 1: Stock Performance - Pagoda Biopharma-B's stock rose by 7.03%, reaching HKD 70, with a trading volume of HKD 770,000 [1]. Group 2: Lock-up Extension - The cornerstone investor has agreed not to reduce their holdings of relevant H-shares from the end of the original lock-up period until December 31, 2025, indicating confidence in the company's future prospects [1]. Group 3: Product Approval and Market Potential - The National Medical Products Administration has approved the new drug application for the company's core product PB-119, which is expected to drive significant revenue growth from 2026 to 2029 due to its clinical advantages in treating T2DM and weight loss [1]. - The DCF valuation suggests substantial upside potential for the company, with PB-119 demonstrating outstanding safety and long-lasting effects, particularly suitable for elderly diabetes patients, positioning it as a best-in-class option [1].

Core Viewpoint - The company has received notification from its cornerstone investor, Yizhe Kangrui Pharmaceutical (Hong Kong) Co., Ltd., agreeing to extend the lock-up period for its H shares until December 31, 2025, indicating confidence in the company's future prospects based on its technological advancements and significant clinical milestones achieved [1] Group 1 - The cornerstone investor will not reduce its holdings in any related H shares from the expiration of the original lock-up period [1] - The extension of the lock-up period reflects the cornerstone investor's confidence in the company's research and development capabilities [1] - The cornerstone investor will continue to review the company's performance and may consider further extending the lock-up period based on real-time developments and achieved milestones [1]

Core Viewpoint - The announcement highlights the extension of the lock-up period for cornerstone investor Yizhe Kangrui Pharmaceutical (Hong Kong) Co., Ltd., indicating confidence in the company's future prospects based on its technological advancements and significant clinical milestones achieved [1] Group 1: Lock-up Agreement - The company entered into a cornerstone investment agreement with Yizhe Kangrui Pharmaceutical, which includes a lock-up commitment for a total of 9,584,500 H shares for a period of 6 months from the listing date [1] - The cornerstone investor currently holds 9,584,500 H shares, representing approximately 3.43% of the company's total issued H shares [1] Group 2: Extension of Lock-up Period - The cornerstone investor has agreed not to reduce their holdings of the relevant H shares from the end of the original lock-up period until December 31, 2025 [1] - The company interprets the extension of the lock-up period as a sign of the cornerstone investor's confidence in the company's ability to advance its technological research and achieve significant clinical milestones [1] - The cornerstone investor will continue to review the company's performance and may consider further extending the lock-up period based on real-time developments and achieved milestones [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 PegBio Co., Ltd. 派格生物醫藥（杭州）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2565） 自願公告 有關基石投資者作出自願延長禁售期的通知 本公告由派格生物醫藥（杭州）股份有限公司（「本公司」）自願刊發。 茲提述本公司日期為2025年5月19日的招股章程及本公司日期為2025年5月26日 的最終發售價及配發結果公告，內容有關（其中包括）(i)本公司與益澤康瑞醫藥 （香港）有限公司（「基石投資者」）訂立的基石投資協議；及(ii)基石投資者就合共 9,584,500股本公司H股作出自上市日期（包括該日）起計六個月期間（「原禁售期」） 的禁售承諾。原禁售期的最後一天為2025年11月26日。截至本公告日期，基石投 資者合共持有9,584,500股H股，佔本公司已發行H股總數約3.43%（「相關H股」）。 近日，本公司接獲基石投資者的通知，據此，基石投資者同意自原禁售 ...

Core Insights - Three innovative drugs have made significant progress, potentially stabilizing the Hang Seng Biotechnology Index and the Hang Seng Innovative Drug Index [1] Group 1: Drug Developments - Innovent Biologics announced that its drug IBI362 (Mastuzumab Injection) has achieved primary and all key secondary endpoints in a Phase III clinical trial for moderate to severe obesity in China, with plans to submit a new drug application for weight control [1] - Junshi Biosciences' PD-1 inhibitor, H drug (Surulitinib), has been officially included in the NMPA's list of breakthrough therapies for perioperative treatment of gastric cancer, marking it as the first drug recognized for this indication [2] - Peijia Medical's PB-119 has received approval from the NMPA for its new drug application, leveraging unique PEGylation technology to enhance efficacy while reducing immunogenicity and gastrointestinal side effects [3] Group 2: Industry Trends - The introduction of the innovative drug directory by commercial insurance is expected to address the accessibility and affordability of high-priced innovative drugs, with policies increasingly favoring the development of high-quality innovative drugs [3] - Chinese innovative pharmaceutical companies are increasingly focusing on internationalization, transitioning from imitation to innovation, supported by favorable policies and abundant clinical resources [2][3] - The ongoing drug review reforms are releasing dividends that are propelling the Chinese innovative drug industry into a new era of "innovation output" [2]

Group 1 - Three innovative drugs have made significant progress, potentially stabilizing the Hang Seng Biotechnology Index and the Hang Seng Innovative Drug Index [1] - Innovent Biologics announced that its drug IBI362 has achieved primary and all key secondary endpoints in a Phase III clinical trial for obesity, with plans to submit a new drug application for weight control [1] - The drug IBI362 is a dual receptor agonist for glucagon and GLP-1, and is the first of its kind approved globally for obesity and type 2 diabetes management [1] Group 2 - Junshi Biosciences' PD-1 inhibitor, H drug, has been officially included in the breakthrough therapy list by the NMPA for use in perioperative treatment of gastric cancer, marking a significant recognition of its clinical value [2] - This breakthrough designation is expected to accelerate the review and approval process for H drug, filling a gap in immune therapy for gastric cancer [2] - The approval of PB-119 by the NMPA highlights the competitive advantage of the drug based on solid clinical data and innovative PEGylation technology, which balances efficacy and reduces side effects [1][3] Group 3 - The introduction of the innovative drug directory by commercial insurance is expected to address the accessibility and affordability of high-priced innovative drugs [3] - The National Healthcare Security Administration is encouraging the high-quality development of innovative drugs, indicating a warming trend in payment policies for innovative drugs [3] - Domestic pharmaceutical companies are actively transitioning towards innovation, supported by ongoing reforms in drug approval processes [3] Group 4 - Relevant Hong Kong stocks in the innovative drug sector include Heng Rui Medicine, Kelun-Botai Biopharmaceutical, and others, indicating a growing interest in the market [4]

每经AI快讯，派格生物医药-B(02565.HK)涨超5%，截至发稿，涨5.11%，报63.8港元，成交额2925.59万 港元。 ...

Core Viewpoint - The approval of PB-119 by the National Medical Products Administration of China marks a significant milestone for the company, enhancing its product portfolio and commercial prospects [1] Group 1: Product Approval - The National Medical Products Administration of China has approved the new drug application for PB-119, a core product of the company [1] - PB-119 is a next-generation long-acting GLP-1 receptor agonist that requires weekly administration [1] - The product is recognized as a "major new drug creation" under a national science and technology major project, classifying it as a Category 1 original drug [1] Group 2: Strategic Partnerships - The company has entered into a strategic partnership with PDC FZ-LLC, a leading pharmaceutical research institution in the UAE [1] - This partnership grants PDC exclusive rights to develop, distribute, market, and commercialize the company's core product Visepegenatide (PB-119) in the Middle East and Africa [1] - The collaboration signifies a critical step in the company's global commercialization strategy [1] Group 3: Market Performance - The company's stock has seen an increase of over 5%, specifically a rise of 5.11%, reaching HKD 63.8, with a trading volume of HKD 29.2559 million [1]

Core Viewpoint - The approval of PB-119 by the National Medical Products Administration of China marks a significant milestone for the company, enhancing its market position and potential revenue streams [1] Company Developments - The company's stock price increased by 5.11%, reaching HKD 63.8, with a trading volume of HKD 29.2559 million [1] - PB-119 is a new generation long-acting GLP-1 receptor agonist, administered once a week, and recognized as a Class 1 new drug by the national major science and technology project [1] - The company has established a strategic partnership with PDC FZ-LLC, granting exclusive rights for the development, distribution, marketing, and commercialization of PB-119 in the Middle East and Africa [1] Industry Impact - The approval of PB-119 is expected to contribute to the advancement of innovative drug development within the biopharmaceutical industry in China [1] - The collaboration with PDC represents a critical step in the company's global commercialization strategy, potentially expanding its market reach [1]